Clinical Trials at Colorado Blood Cancer Institute
As of June 2026, 69 paid clinical trials are recruiting at Colorado Blood Cancer Institute, located at 7535 E HAMPDEN AVE STE 400, DENVER, CO 80231-4844, phone (303) 276-4146 in Denver, Colorado. Active studies at this site cover conditions such as Breast Cancer, Multiple Myeloma and Advanced Solid Tumor. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
69 clinical trials at Colorado Blood Cancer Institute
·Clear filters·↓ Download CSVA Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A Study of CTD402 in T-ALL/LBL Patients
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Mobile Health for Adherence in Breast Cancer Patients
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
About research studies in Denver
Denver has approximately 561 recruiting research studies across a wide range of therapeutic areas. Colorado hosts the University of Colorado Anschutz Medical Campus, National Jewish Health, and Children's Hospital Colorado, with strong programs in pulmonology, oncology, and cardiovascular research.
Common conditions studied in Denver
- Breast Cancer (20 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Multiple Myeloma (16 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Advanced Solid Tumor (15 active studies). Recruiting Advanced Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Solid Tumor (11 active studies). Recruiting Solid Tumor studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Cystic Fibrosis (10 active studies). Recruiting Cystic Fibrosis studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Endometrial Cancer (10 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in Denver
- University of Colorado, Denver
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
- SWOG Cancer Research Network
Local regulations and guidelines
Clinical trials in Colorado are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Colorado trials are additionally subject to the Colorado Privacy Act (CPA), which adds consumer data-protection requirements to federal baseline standards.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Denver. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Denver
Hipa.ai aggregates every recruiting study in Denver from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Denver?
There are approximately 561 recruiting clinical trials in Denver, Colorado listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Denver pay participants?
Most recruiting trials in Denver compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Denver?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Denver?
The most common conditions under active study in Denver include Breast Cancer (20), Multiple Myeloma (16), Advanced Solid Tumor (15), Solid Tumor (11), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Denver?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Denver on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Denver?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Denver?
Recruiting research sites in Denver include Colorado Blood Cancer Institute, National Jewish Health, AdventHealth Porter, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Denver right now?
The largest active categories in Denver are Cancer & tumors (249), Cardiovascular (18), Diabetes & metabolic (10). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Colorado Blood Cancer Institute?
Colorado Blood Cancer Institute is located at 7535 E HAMPDEN AVE STE 400, DENVER, CO 80231-4844. Use the Google Maps link in the intro above to get directions.
How do I contact Colorado Blood Cancer Institute?
You can reach Colorado Blood Cancer Institute by phone at (303) 276-4146. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.